Copyright Notice
Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.
Bookshelf ID: NBK513063PMID: 30000993
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.
CASRN: 606143-89-9
Drug Levels and Effects
Summary of Use during Lactation
No information is available on the clinical use of binimetinib during breastfeeding. Because binimetinib is 97% bound to plasma proteins, and the half-life of the drug is 3.5 hours, the amount in milk is likely to be low. However, the manufacturer recommends that breastfeeding be discontinued during binimetinib therapy and for at least 3 days after the final dose. For patients taking the combination with encorafenib, the manufacturer recommends that breastfeeding be discontinued during binimetinib therapy and for at least 2 weeks after the final dose.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Substance Identification
Substance Name
Binimetinib
CAS Registry Number
606143-89-9
Drug Class
Breast Feeding
Antineoplastic Agents
Enzyme Inhibitors
Protein Kinase Inhibitors
Signal Transduction Inhibitors
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- User and Medical Advice Disclaimer
- Drugs and Lactation Database (LactMed) - Record Format
- LactMed - Database Creation and Peer Review Process
- Fact Sheet. Drugs and Lactation Database (LactMed)
- Drugs and Lactation Database (LactMed) - Glossary
- LactMed Selected References
- Drugs and Lactation Database (LactMed) - About Dietary Supplements
- Breastfeeding Links
- PubChem SubstanceRelated PubChem Substances
- Review Acalabrutinib.[Drugs and Lactation Database (...]Review Acalabrutinib.. Drugs and Lactation Database (LactMed®). 2006
- Review Regorafenib.[Drugs and Lactation Database (...]Review Regorafenib.. Drugs and Lactation Database (LactMed®). 2006
- Review Osimertinib.[Drugs and Lactation Database (...]Review Osimertinib.. Drugs and Lactation Database (LactMed®). 2006
- Review Dacomitinib.[Drugs and Lactation Database (...]Review Dacomitinib.. Drugs and Lactation Database (LactMed®). 2006
- Review Glasdegib.[Drugs and Lactation Database (...]Review Glasdegib.. Drugs and Lactation Database (LactMed®). 2006
- Binimetinib - Drugs and Lactation Database (LactMed®)Binimetinib - Drugs and Lactation Database (LactMed®)
Your browsing activity is empty.
Activity recording is turned off.
See more...